Background Nitric oxide (NO) is a major endogenous regulator of vascular tone. Inhaled
nitric oxide (iNO) gas has been investigated as treatment for persistent pulmonary …

Inhaled nitric oxide (iNO) acts as a selective pulmonary vasodilator and it is currently
approved by the FDA for the treatment of persistent pulmonary hypertension of the newborn …

Pulmonary hypertension is associated with diverse cardiac, pulmonary, and systemic
diseases in neonates, infants, and older children and contributes to significant morbidity and …

Failure of the normal circulatory adaptation to extrauterine life results in persistent
pulmonary hypertension of the newborn (PPHN). Although this condition is most often …

Objective To evaluate the efficacy, safety, and pharmacokinetics of the endothelin receptor
antagonist bosentan as adjunctive therapy for neonates with persistent pulmonary …

The fetal circulation uses a series of adaptive mechanisms to maximize delivery of oxygen to
the most metabolically active tissues. Blood returning from the placenta through the …

Recent advances in our understanding of neonatal pulmonary circulation and the underlying
pathophysiology of hypoxemic respiratory failure (HRF)/persistent pulmonary hypertension …

Persistent pulmonary hypertension (PPHN) is a consequence of failed pulmonary vascular
transition at birth and leads to pulmonary hypertension with shunting of deoxygenated blood …

Background Pulmonary hypertension (PH) is an important contributor of morbidity and
mortality in infants with congenital diaphragmatic hernia (CDH). Treatment options are …

BACKGROUND The oxygenation index (mean airway pressure× FIO 2 divided by PaO 2)
was originally devised to measure severity of illness and predict outcome in neonatal …